Abstract Number: 597 • 2017 ACR/ARHP Annual Meeting
Ixekizumab Improves Patient-Reported Outcomes through 52 Weeks in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to Tumor Necrosis Factor-Inhibitors
Background/Purpose: Ixekizumab (IXE) is a high affinity monoclonal antibody that selectively targets interleukin-17A. Up to 24 weeks, IXE was superior to placebo (PBO) in improving…Abstract Number: 612 • 2017 ACR/ARHP Annual Meeting
Safety and Effectiveness of Ustekinumab for the Treatment of Psoriatic Arthritis over a 6 Month Period
Background/Purpose: Ustekinumab (UST) is a fully human immunoglobin monoclonal antibody against interleukin-12 (IL-12) and interleukin-23 (IL-23) that has been proven safe and efficacious for the…Abstract Number: 1232 • 2017 ACR/ARHP Annual Meeting
The Perceived Impact of Recent-Onset Psoriatic Arthritis Is Different between Genders: A Spanish Multicenter Experience
Background/Purpose: Some studies point to a differential clinical expression between men and women with PsA, but the information on gender differences is very scarce in…Abstract Number: 1531 • 2017 ACR/ARHP Annual Meeting
Effects of Intravenous Golimumab on Patient-Reported Outcomes in Active Ankylosing Spondylitis: 28-Week Results of the Phase 3 Trial
Background/Purpose: To evaluate patient-reported outcomes (PRO) of physical functioning, mental health functioning, health state, and health-related quality of life (HRQoL) in patients (pts) with active…Abstract Number: 2248 • 2017 ACR/ARHP Annual Meeting
Function, Pain, Fatigue, and Participation Are the Primary Contributors to the Patient Global Assessment in Rheumatoid Arthritis
Background/Purpose: The patient global assessment (PGA) is widely used in disease activity scores for RA, including the CDAI, SDAI, and DAS28. While pain has been…Abstract Number: 2463 • 2017 ACR/ARHP Annual Meeting
Golimumab in Biologic-NaïVe Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Subanalysis from a Non-Interventional Evaluation in Germany
Background/Purpose: Golimumab (GLM) has demonstrated efficacy and safety in several randomized clinical trials with biologic-naïve patients (pts.). However, more data regarding the effectiveness and patient-reported…Abstract Number: 2539 • 2017 ACR/ARHP Annual Meeting
The Contribution of Skin and Joint Improvements to the Health-Related Quality of Life of Patients with Active Psoriatic Arthritis
Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease affecting peripheral and axial joints. For patients with active psoriasis, the added burden of skin…Abstract Number: 2548 • 2017 ACR/ARHP Annual Meeting
Validation of New Potential Targets for Remission and Low Disease Activity in Psoriatic Arthritis in Patients Treated with Golimumab
Background/Purpose: Treat to target recommendations in PsA state that the target of treatment should be remission or low disease activity (LDA). So far, the only…Abstract Number: 2549 • 2017 ACR/ARHP Annual Meeting
Achievement of Minimal Disease Activity Is Associated with Improvements in Health-Related Quality of Life and Productivity in Psoriatic Arthritis Patients
Background/Purpose: Treatment goals in psoriatic arthritis (PsA) are moving toward attainment of absolute therapeutic thresholds rather than relative improvement. Minimal disease activity (MDA), a composite…Abstract Number: 2373 • 2016 ACR/ARHP Annual Meeting
Patient Preference for Display of Electronic Patient-Reported Outcomes in Osteoarthritis Clinical Trials: Wording Emphasis, Question Format, and Navigation Button Placement
Background/Purpose: Electronic patient-reported outcomes (ePROs) are a reliable method for collecting patient data in osteoarthritis clinical trials and offer many advantages over paper collection; however,…Abstract Number: 2501 • 2016 ACR/ARHP Annual Meeting
Radiographic Damage in Patients with RA Increases By 8.3% per Year Disease Duration, in the Era of Biologic Dmards. Results from the Scqm Cohort
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory disease leading to joint destructions, if untreated. Treatment with biologic DMARDs has shown to favourably influence disease…Abstract Number: 2635 • 2016 ACR/ARHP Annual Meeting
Using Patient Reported Outcomes to Inform a Treat to Target Treatment Approach in RA
Background/Purpose: The Patient Reported Outcomes Measurement Information System (PROMIS) is an NIH initiative to develop patient-reported outcome measures (PROs) for use across chronic conditions. PROMIS…Abstract Number: 2679 • 2016 ACR/ARHP Annual Meeting
Clinically Meaningful Improvement of Essdai and Esspri in Patients with Primary SjöGren’s Syndrome in Real Life: A 12-Month Longitudinal Study
Background/Purpose: The increasing use of ESSDAI and patient reported outcomes (PROs) in primary Sjögren’s syndrome (pSS) clinical trials has pointed out that the performance of…Abstract Number: 2743 • 2016 ACR/ARHP Annual Meeting
Do Specific Entheseal Points in Spa Patients Impact Patient Reported Outcomes? Implications for Clinical Practice
Background/Purpose: Previous studies have shown associations between swelling or tenderness of specific joints in RA patients and patient pain. This analysis aimed to describe the…Abstract Number: 103 • 2016 ACR/ARHP Annual Meeting
People with Rheumatoid Arthritis Recruited from an Online Patient Community May Differ from Clinical Populations in Symptoms and Impacts
Background/Purpose: Patients are increasingly recruited from online communities to provide insight regarding their lived experiences and preferences for treatment and services. We compared physical, social,…